Business Context and Reporting Period
Company: Rexahn Pharmaceuticals, Inc. (Note: Metadata listed "Opus Genetics," but the filing text identifies the registrant as Rexahn Pharmaceuticals, Inc.)
Period: Quarterly period ended March 31, 2010
Status: Development stage biopharmaceutical company focused on cancer, CNS disorders, and sexual dysfunction. The company has no commercial product sales to date and relies on equity financing, debt, and collaboration agreements to fund operations.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | Cumulative (Inception to Mar 31, 2010) |
|---|---|---|---|
| Revenue | $18,750 | $18,750 | $543,750 |
| Total Expenses | $1,611,868 | $1,511,161 | $37,674,086 |
| Net Loss | $(1,571,104) | $(1,484,802) | $(37,865,011) |
| Cash & Equivalents (End of Period) | $7,682,191 | $1,859,980 | N/A |
| Restricted Cash Equivalents | $1,909,827 | N/A | N/A |
| Operating Cash Flow | $(1,049,045) | $(1,056,971) | $(30,532,959) |
| Financing Cash Flow | $1,318,241 | $0 | $41,210,506 |
| Accumulated Deficit | $(37,865,011) | N/A | $(37,865,011) |
Liquidity: Total assets were $10.4 million, with total liabilities of $2.0 million. The company reported a net increase in cash of $384,159 for the quarter, driven primarily by proceeds from the exercise of stock warrants ($1.3 million).
Material Changes vs. Prior Period
- Revenue: Remained flat at $18,750, derived entirely from the amortization of a deferred revenue agreement with Rexgene Biotech Co., Ltd.
- Expenses: General and Administrative (G&A) expenses increased 46.1% to $1.06 million, primarily due to professional fees and investor relations. Research and Development (R&D) expenses decreased 32.0% to $491,122 due to the completion of ongoing clinical trials.
- Net Loss: Increased slightly to $1.57 million compared to $1.48 million in the prior year quarter.
- Capital Structure: Significant cash inflow from financing activities ($1.3 million) in Q1 2010 compared to zero in Q1 2009, resulting from warrant and option exercises.
Outlook, Risks, and Management Commentary
Outlook & Guidance: Management believes existing cash resources are sufficient to cover minimum operating needs through March 31, 2011. The company anticipates incurring losses for the remainder of fiscal 2010 and beyond. Future funding is required to complete Phase II trials for lead candidates (Archexin, Serdaxin, Zoraxel) and pre-clinical work for RX-3117.
Key Risks:
- Liquidity Risk: The company has no commercial revenue and must raise additional capital to continue operations. Failure to secure financing may force a reduction in R&D activities.
- Development Risk: Two lead candidates (Serdaxin and Zoraxel) share the same active ingredient (clavulanic acid); safety concerns with this ingredient could jeopardize both programs.
- Legal Proceedings: A lawsuit filed by Amarex, LLC seeking $93,156 in damages is pending, with a trial scheduled for June 14, 2010. The company has filed a counterclaim for $354,824.
- Contractual Obligations: Approximately $5.2 million remains to be paid on R&D service agreements. A $2 million commitment exists for the pre-clinical development of RX-3117 under an agreement with Teva Pharmaceutical.
Investor Verification Checklist
- Cash Runway: Verify if the $7.7 million cash balance is sufficient to fund the estimated $3 million in clinical trial costs and $4 million in corporate expenses projected for the next 12 months.
- Financing Needs: Assess the likelihood of securing additional equity or debt financing given the company's development stage status and lack of revenue.
- Legal Exposure: Monitor the outcome of the Amarex, LLC litigation scheduled for June 2010.
- Drug Development Progress: Confirm the status of Phase II trials for Archexin (pancreatic cancer), Serdaxin (depression), and Zoraxel (erectile dysfunction), and the pre-clinical timeline for RX-3117.
- Restricted Cash: Note that $1.9 million of cash is restricted for the Teva RX-3117 program and a letter of credit for office lease obligations.